Trabectedin for the treatment of breast cancer

Expert Opinion on Investigational Drugs

Volumn 25, Issue 1, 2016, Pages 105-115

  Dincalci, Maurizio ^a   Zambelli, Alberto ^b  

^a MARIO NEGRI INSTITUTE FOR PHARMACOLOGICAL RESEARCH   (Italy)

^b PAPA GIOVANNI XXIII HOSPITAL   (Italy)

Author keywords

BRCA mutation; DNA repair; metastatic breast cancer; trabectedin

Indexed keywords

TRABECTEDIN; 1,3 DIOXOLANE DERIVATIVE; ALKYLATING AGENT; TETRAHYDROISOQUINOLINE DERIVATIVE;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; BREAST METASTASIS; CANCER SURVIVAL; CELL CYCLE ARREST; DNA CROSS LINKING; DNA REPAIR; DNA SYNTHESIS INHIBITION; DOSE RESPONSE; DRUG DNA INTERACTION; DRUG HALF LIFE; DRUG INDICATION; DRUG MECHANISM; EXCISION REPAIR; GENE EXPRESSION; HUMAN; OVARY CANCER; OVERALL SURVIVAL; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PROGRESSION FREE SURVIVAL; SOFT TISSUE SARCOMA; TUMOR ASSOCIATED LEUKOCYTE; TUMOR GROWTH; TUMOR IMMUNITY; TUMOR MICROENVIRONMENT; ANIMAL; BREAST NEOPLASMS; DRUG EFFECTS; FEMALE; METASTASIS; PATHOLOGY;

ANIMALS; ANTINEOPLASTIC AGENTS, ALKYLATING; BREAST NEOPLASMS; DIOXOLES; DNA REPAIR; FEMALE; HUMANS; NEOPLASM METASTASIS; TETRAHYDROISOQUINOLINES; TUMOR MICROENVIRONMENT;

EID: 84954386070     PISSN: 13543784     EISSN: 17447658     Source Type: Journal    
DOI: 10.1517/13543784.2016.1124086     Document Type: Article

References (74)

1. D'Incalci M, Galmarini CM. A review of trabectedin (ET-743): A unique mechanism of action. Mol Cancer Ther. 2010 Aug;9 (8):2157-2163.
2. Erba E, Bergamaschi D, Bassano L, et al. Ecteinascidin-743 (ET-743), a natural marine compound, with a unique mechanism of action. Eur J Cancer. 2001 Jan;37(1):97-105.
3. Tavecchio M, Simone M, Erba E, et al. Role of homologous recombination in trabectedin-induced DNA damage. Eur J Cancer. 2008 Mar;44(4):609-618.
4. Soares DG, Escargueil AE, Poindessous V, et al. Replication and homologous recombination repair regulate DNA doublestrand break formation by the antitumor alkylator ecteinascidin 743. Proc Natl Acad Sci U S A. 2007 Aug 7;104 (32):13062-13067.
5. Damia G, Silvestri S, Carrassa L, et al. Unique pattern of ET-743 activity in different cellular systems with defined deficiencies in DNA-repair pathways. Int J Cancer. 2001 May 15;92(4):583-588.
6. Takebayashi Y, Pourquier P, Zimonjic DB, et al. Antiproliferative activity of ecteinascidin 743 is dependent upon transcription-coupled nucleotide-excision repair. Nat Med. 2001 Aug;7(8):961-966.
7. Tavecchio M, Natoli C, Ubezio P, et al. Dynamics of cell cycle phase perturbations by trabectedin (ET-743) in nucleotide excision repair (NER)-deficient and NERproficient cells, unravelled by a novel mathematical simulation approach. Cell Prolif. 2007 Dec;40(6):885-904.
8. Uboldi S, Bernasconi S, Romano M, et al. Characterization of a new trabectedinresistant myxoid liposarcoma cell line that shows collateral sensitivity to methylating agents. Int J Cancer. 2012 Jul 1;131 (1):59-69.
9. Colmegna B, Uboldi S, Erba E, et al. Resistance to minor groove binders. Drug Discov Today Technol. 2014 Mar;11:73-79.
10. Minuzzo M, Ceribelli M, Pitarque-Marti M, et al. Selective effects of the anticancer drug Yondelis (ET-743) on cell-cycle promoters. Mol Pharmacol. 2005 Nov;68 (5):1496-1503.
11. Jin S, Gorfajn B, Faircloth G, et al. Ecteinascidin 743, a transcription-targeted chemotherapeutic that inhibits MDR1 activation. Proc Natl Acad Sci U S A. 2000 Jun 6;97(12):6775-6779.
12. Forni C, Minuzzo M, Virdis E, et al. Trabectedin (ET-743) promotes differentiation in myxoid liposarcoma tumors. Mol Cancer Ther. 2009 Feb;8(2):449-457.
13. Di Giandomenico S, Frapolli R, Bello E, et al. Mode of action of trabectedin in myxoid liposarcomas. Oncogene. 2014 Oct 30;33(44):5201-5210.
14. Aune GJ, Takagi K, Sordet O, et al. Von Hippel-Lindau-coupled and transcriptioncoupled nucleotide excision repair-dependent degradation of RNA polymerase II in response to trabectedin. Clin Cancer Res. 2008 Oct 15;14(20):6449-6455.
15. Feuerhahn S, Giraudon C, Martinez-Diez M, et al. XPF-dependent DNA breaks and RNA polymerase II arrest induced by antitumor DNA interstrand crosslinkingmimetic alkaloids. Chem Biol. 2011 Aug 26;18(8):988-999.
16. Germano G, Frapolli R, Belgiovine C, et al. Role of macrophage targeting in the antitumor activity of trabectedin. Cancer Cell. 2013 Feb 11;23(2):249-262.
17. Germano G, Frapolli R, Simone M, et al. Antitumor and anti-inflammatory effects of trabectedin on human myxoid liposarcoma cells. Cancer Res. 2010 Mar 15;70 (6):2235-2244.
18. D'Incalci M, Badri N, Galmarini CM, et al. Trabectedin, a drug acting on both cancer cells and the tumour microenvironment. Br J Cancer. 2014;111(4):646-650.
19. D'Incalci M, Frapolli R, Germano G, et al. New activities for the anti-tumor agent trabectedin: Taking two birds with one stone. Oncotarget. 2013 Apr;4 (4):496-497.
20. Dossi R, Frapolli R, Di Giandomenico S, et al. Antiangiogenic activity of trabectedin in myxoid liposarcoma: Involvement of host TIMP-1 and TIMP-2 and tumor thrombospondin-1. Int J Cancer. 2015 Feb 1;136(3):721-729.
21. Atmaca H, Uzunoglu S. Anti-angiogenic effects of trabectedin (Yondelis; ET-743) on human breast cancer cells. Eur Cytokine Netw. 2014 Mar 1;25(1):1-7.
22. Jimeno J, Faircloth G, Cameron L. Progress in the acquisition of new marine-derived anticancer compounds: Development of ecteinascidin-743 (et-743). Drugs Future. 1996;21:1155-1165.
23. Izbicka E, Lawrence R, Raymond E, et al. In vitro antitumor activity of the novel marine agent, ecteinascidin-743 (ET-743, NSC-648766) against human tumors explanted from patients. Ann Oncol. 1998 Sep;9(9):981-987.
24. Gajate C, An F, Mollinedo F. Differential cytostatic and apoptotic effects of ecteinascidin-743 in cancer cells. Transcription-dependent cell cycle arrest and transcription-independent JNK and mitochondrial mediated apoptosis. J Biol Chem. 2002 Nov 1;277(44):41580-41589.
25. Debatin KM. Apoptosis pathways in cancer and cancer therapy. Cancer Immunol Immunother. 2004 Mar;53(3):153-159.
26. Riedl SJ, Salvesen GS. The apoptosome: Signalling platform of cell death. Nat Rev Mol Cell Biol. 2007 May;8(5):405-413.
27. Atmaca H, Bozkurt E, Uzunoglu S, et al. A diverse induction of apoptosis by trabectedin in MCF-7 (HER2-/ER+) and MDA-MB-453 (HER2+/ER-) breast cancer cells. Toxicol Lett. 2013 Aug 14;221 (2):128-136.
28. Peto J, Collins N, Barfoot R, et al. Prevalence of BRCA1 and BRCA2 gene mutations in patients with early-onset breast cancer. J Natl Cancer Inst. 1999 Jun 2;91(11):943-949.
29. Turner N, Tutt A, Ashworth A. Hallmarks of 'BRCAness' in sporadic cancers. Nat Rev Cancer. 2004 Oct;4(10):814-819.
30. Garcia MJ, Saucedo-Cuevas LP, Munoz-Repeto I, et al. Analysis of DNA repairrelated genes in breast cancer reveals CUL4A ubiquitin ligase as a novel biomarker of trabectedin response. Mol Cancer Ther. 2013 Apr;12(4):530-541.
31. Avila S, Martinez M, Moneo V, et al. Synergistic combination of trabectedin and olaparib in breast cancer tumor cell lines. American Association for Cancer Research, 105th Annual meeting; 2014 Apr 5-9; San Diego, CA; p. 1686.
32. Takahashi N, Li W, Banerjee D, et al. Sequence-dependent synergistic cytotoxicity of ecteinascidin-743 and paclitaxel in human breast cancer cell lines in vitro and in vivo. Cancer Res. 2002 Dec 1;62 (23):6909-6915.
33. Taamma A, Misset JL, Riofrio M, et al. Phase I and pharmacokinetic study of ecteinascidin-743, a new marine compound, administered as a 24-hour continuous infusion in patients with solid tumors. J Clin Oncol. 2001 Mar 1;19 (5):1256-1265.
34. Sessa C, Cresta S, Noberasco C, et al. Phase I clinical and pharmacokinetic study of trabectedin and cisplatin in solid tumours. Eur J Cancer. 2009;45 (12):2116-2122.
35. Chu Q, Mita A, Forouzesh B, et al. Phase I and pharmacokinetic study of sequential paclitaxel and trabectedin every 2 weeks in patients with advanced solid tumors. Clin Cancer Res. 2010 May 1;16(9):2656-2665.
36. Forouzesh B, Hidalgo M, Chu Q, et al. Phase I and pharmacokinetic study of trabectedin as a 1-or 3-hour infusion weekly in patients with advanced solid malignancies. Clin Cancer Res. 2009 May 15;15 (10):3591-3599.
37. Gore L, Rivera E, Basche M, et al. Phase I combination study of trabectedin and capecitabine in patients with advanced malignancies. Invest New Drugs. 2012;30 (5):1942-1949.
38. Messersmith WA, Jimeno A, Ettinger D, et al. Phase I trial of weekly trabectedin (ET-743) and gemcitabine in patients with advanced solid tumors. Cancer Chemother Pharmacol. 2008;63(1):181-188.
39. Ryan DP, Supko JG, Eder JP, et al. Phase I and pharmacokinetic study of ecteinascidin 743 administered as a 72-hour continuous intravenous infusion in patients with solid malignancies. Clin Cancer Res. 2001;7 (2):231-242.
40. Sessa C, Perotti A, Noberasco C, et al. Phase I clinical and pharmacokinetic study of trabectedin and doxorubicin in advanced soft tissue sarcoma and breast cancer. Eur J Cancer. 2009 May;45 (7):1153-1161.
41. Twelves C, Hoekman K, Bowman A, et al. Phase I and pharmacokinetic study of Yondelis (Ecteinascidin-743; ET-743) administered as an infusion over 1 h or 3 h every 21 days in patients with solid tumours. Eur J Cancer. 2003;39 (13):1842-1851.
42. van Kesteren C, Cvitkovic E, Taamma A, et al. Pharmacokinetics and pharmacodynamics of the novel marine-derived anticancer agent ecteinascidin 743 in a phase I dose-finding study. Clin Cancer Res. 2000;6(12):4725-4732.
43. Vidal L, Magem M, Barlow C, et al. Phase I clinical and pharmacokinetic study of trabectedin and carboplatin in patients with advanced solid tumors. Invest New Drugs. 2012;30(2):616-628.
44. Villalona-Calero MA, Eckhardt SG, Weiss G, et al. A phase I and pharmacokinetic study of ecteinascidin-743 on a daily x 5 schedule in patients with solid malignancies. Clin Cancer Res. 2002;8(1):75-85.
45. von Mehren M, Bookman M, Meropol NJ, et al. Phase I study of the safety and pharmacokinetics of trabectedin with docetaxel in patients with advanced malignancies. Cancer Chemother Pharmacol. 2015;75(5):1047-1055.
46. von Mehren M, Schilder RJ, Cheng JD, et al. A phase I study of the safety and pharmacokinetics of trabectedin in combination with pegylated liposomal doxorubicin in patients with advanced malignancies. Ann Oncol. 2008;19(10):1802-1809.
47. Le Cesne A, Yovine A, Blay JY, et al. A retrospective pooled analysis of trabectedin safety in 1,132 patients with solid tumors treated in phase II clinical trials. Invest New Drugs. 2012;30(3):1193-1202.
48. Goldstein LJ, Gurtler J, Del Prete SA, et al. Trabectedin as a single-agent treatment of advanced breast cancer after anthracycline and taxane treatment: A multicenter, randomized, phase II study comparing 2 administration regimens. Clin Breast Cancer. 2014;14(6):396-404.
49. Delaloge S, Wolp-Diniz R, Byrski T, et al. Activity of trabectedin in germline BRCA1/2-mutated metastatic breast cancer: Results of an international first-in-class phase II study. Ann Oncol. 2014 Jun;25 (6):1152-1158.
50. Awada A, Cortes J, Martin M, et al. Final results of a phase II trial of trabectedin (T) in patients with hormone receptor-positive, HER2-negative advanced breast cancer, according to xeroderma pigmentosum gene (XPG) expression. American Society of Clinical Oncology, 49th Annual Meeting; 2013 May 31-Jun 4; Chicago, IL. J Clin Oncol. 31(Supl 15):547.
51. Bui-Nguyen B, Butrynski JE, Penel N, et al. A phase IIb multicentre study comparing the efficacy of trabectedin to doxorubicin in patients with advanced or metastatic untreated soft tissue sarcoma: The TRUSTS trial. Eur J Cancer. 2015;51 (10):1312-1320.
52. Kawai A, Araki N, Sugiura H, et al. Trabectedin monotherapy after standard chemotherapy versus best supportive care in patients with advanced, translocationrelated sarcoma: A randomised, open-label, phase 2 study. Lancet Oncol. 2015;16 (4):406-416.
53. Pautier P, Floquet A, Chevreau C, et al. Trabectedin in combination with doxorubicin for first-line treatment of advanced uterine or soft-tissue leiomyosarcoma (LMS-02): A non-randomised, multicentre, phase 2 trial. Lancet Oncol. 2015;16 (4):457-464.
54. Le Cesne A, Blay JY, Domont J, et al. Interruption versus continuation of trabectedin in patients with soft-tissue sarcoma (T-DIS): A randomised phase 2 trial. Lancet Oncol. 2015;16(3):312-319.
55. Massuti B, Cobo M, Camps C, et al. Trabectedin in patients with advanced non-small-cell lung cancer (NSCLC) with XPG and/or ERCC1 overexpression and BRCA1 underexpression and pretreated with platinum. Lung Cancer. 2012;76 (3):354-361.
56. Monk BJ, Blessing JA, Street DG, et al. A phase II evaluation of trabectedin in the treatment of advanced, persistent, or recurrent uterine leiomyosarcoma: A gynecologic oncology group study. Gynecol Oncol. 2012 Jan;124(1):48-52.
57. Michaelson MD, Bellmunt J, Hudes GR, et al. Multicenter phase II study of trabectedin in patients with metastatic castration-resistant prostate cancer. Ann Oncol. 2012;23(5):1234-1240.
58. Gronchi A, Bui BN, Bonvalot S, et al. Phase II clinical trial of neoadjuvant trabectedin in patients with advanced localized myxoid liposarcoma. Ann Oncol. 2012;23(3):771-776.
59. Monk BJ, Sill MW, Hanjani P, et al. Docetaxel plus trabectedin appears active in recurrent or persistent ovarian and primary peritoneal cancer after up to three prior regimens: A phase II study of the Gynecologic Oncology Group. Gynecol Oncol. 2011;120(3):459-463.
60. Paz-Ares L, Lopez-Pousa A, Poveda A, et al. Trabectedin in pre-treated patients with advanced or metastatic soft tissue sarcoma: A phase II study evaluating cotreatment with dexamethasone. Invest New Drugs. 2012;30(2):729-740.
61. Demetri GD, Chawla SP, von Mehren M, et al. Efficacy and safety of trabectedin in patients with advanced or metastatic liposarcoma or leiomyosarcoma after failure of prior anthracyclines and ifosfamide: Results of a randomized phase II study of two different schedules. J Clin Oncol. 2009 Sep 1;27(25):4188-4196.
62. Del Campo JM, Roszak A, Bidzinski M, et al. Phase II randomized study of trabectedin given as two different every 3 weeks dose schedules (1.5 mg/m2 24 h or 1.3 mg/m2 3 h) to patients with relapsed, platinum-sensitive, advanced ovarian cancer. Ann Oncol. 2009;20(11):1794-1802.
63. McMeekin DS, Lisyanskaya A, Crispens M, et al. Single-agent trabectedin as second-line therapy of persistent or recurrent endometrial cancer: Results of a multicenter phase II study. Gynecol Oncol. 2009;114(2):288-292.
64. Zambelli A, Tancredi R, Negri S, et al. Trabectedin and indole-3-carbinol combination in heavily pretreated metastatic breast cancer: Results of a pilot clinical study. J Clin Oncol 2014;32(Suppl). Abstract e12015.
65. Zelek L, Yovine A, Brain E, et al. A phase II study of Yondelis (trabectedin, ET-743) as a 24-h continuous intravenous infusion in pretreated advanced breast cancer. Br J Cancer. 2006 Jun 5;94(11):1610-1614.
66. Donald S, Verschoyle RD, Greaves P, et al. Dietary agent indole-3-carbinol protects female rats against the hepatotoxicity of the antitumor drug ET-743 (trabectidin) without compromising efficacy in a rat mammary carcinoma. Int J Cancer. 2004 Oct 10;111(6):961-967.
67. Monk BJ, Ghatage P, Parekh T, et al. Effect of BRCA1 and XPG mutations on treatment response to trabectedin and pegylated liposomal doxorubicin in patients with advanced ovarian cancer: Exploratory analysis of the phase 3 OVA-301 study. Ann Oncol. 2015;26(5):914-920.
68. Byrski T, Huzarski T, Dent R, et al. Pathologic complete response to neoadjuvant cisplatin in BRCA1-positive breast cancer patients. Breast Cancer Res Treat. 2014;147(2):401-405.
69. Kaufman B, Shapira-Frommer R, Schmutzler RK, et al. Olaparib monotherapy in patients with advanced cancer and a germline BRCA1/2 mutation. J Clin Oncol. 2015 Jan 20;33(3):244-250.
70. Adams S, Gray RJ, Demaria S, et al. Prognostic value of tumor-infiltrating lymphocytes in triple-negative breast cancers from two phase III randomized adjuvant breast cancer trials: ECOG 2197 and ECOG 1199. J Clin Oncol. 2014 Sep 20;32(27):2959-2966.
71. Loi S, Michiels S, Salgado R, et al. Tumor infiltrating lymphocytes are prognostic in triple negative breast cancer and predictive for trastuzumab benefit in early breast cancer: Results from the FinHER trial. Ann Oncol. 2014 Aug;25 (8):1544-1550.
72. Ibrahim EM, Al-Foheidi ME, Al-Mansour MM, et al. The prognostic value of tumorinfiltrating lymphocytes in triple-negative breast cancer: A meta-analysis. Breast Cancer Res Treat. 2014 Dec;148(3):467-476.
73. Homet Moreno B, Ribas A. Anti-programmed cell death protein-1/ligand-1 therapy in different cancers. Br J Cancer. 2015Apr 28;112(9):1421-1427.
74. Nanda R, Chow L, Dees EC, et al. A phase Ib study of pembrolizumab (MK-3475) in patients with advanced triplenegative breast cancer San Antonio Breast Cancer Symposium; 2014 Dec 9-13; San Antonio, TX; p. S1-S9.